In clinical trials, the ALK inhibitor crizotinib showed greater benefit than chemotherapy in NSCLC patients presenting with ALK gene rearrangement, resulting in the approval of crizotinib for the treatment of EML4–ALK-positive NSCLC patients (approximately 70,000 patients diagnosed annually worldwide) [23]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.